Neurocrine Biosciences Inc (NBIX): Capital Expenditures
$34.00M
Year ended 2025-12-31
$27.70M
Trailing 12 months to 2026-06-30
+27.3%
3-year compound annual growth
+25.5%
5-year compound annual growth
+33.2%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.00M | -11.0% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $38.20M | +35.0% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $28.30M | +71.5% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $16.50M | -29.5% | 2025-02-10, From 2022-01-01 |
| 2021-12-31 | $23.40M | +114.7% | 2024-02-09, From 2021-01-01 |
| 2020-12-31 | $10.90M | -25.9% | 2023-02-09, From 2020-01-01 |
| 2019-12-31 | $14.70M | -40.7% | 2022-02-11, From 2019-01-01 |
| 2018-12-31 | $24.80M | +257.3% | 2021-02-05, From 2018-01-01 |
| 2017-12-31 | $6.94M | +68.9% | 2020-02-07, From 2017-01-01 |
| 2016-12-31 | $4.11M | +112.4% | 2019-02-08, From 2016-01-01 |
| 2015-12-31 | $1.93M | +20.0% | 2018-02-13, From 2015-01-01 |
| 2014-12-31 | $1.61M | +195.8% | 2017-02-14, From 2014-01-01 |
| 2013-12-31 | $545.0K | -43.9% | 2016-02-11, From 2013-01-01 |
| 2012-12-31 | $971.0K | +29.5% | 2015-02-09, From 2012-01-01 |
| 2011-12-31 | $750.0K | +138.1% | 2014-02-11, From 2011-01-01 |
| 2010-12-31 | $315.0K | +800.0% | 2013-02-08, From 2010-01-01 |
| 2009-12-31 | $35.0K | n/a | 2012-02-09, From 2009-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $34.00M | -11.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $8.43M | -70.4% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $201.05M | +20.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $192.00M | -81.7% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $6.97M | -34.8% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $2.47M | +119.6% |
| Biogen Inc. (BIIB) | 2025-12-31 | $153.80M | +0.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
Compare NBIX, EXEL, QGEN, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗